BIIB vs JCI · P/E 21, rev $9.89B vs P/E 44, rev $23.60B
Biogen Inc (BIIB) versus Johnson Controls International PLC (JCI) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Johnson Controls International PLC (JCI) is a building products & equipment company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported JCI revenue for 2025-09-30 was $23.60B. Net income was $3.51B. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. JCI currently screens at market cap $87.62B and trailing P/E 43.9.
Not investment advice. Open the BIIB and JCI stock pages for the full models.
Not investment advice.